Bexson Biomedical announced today that it received pre-investigational new drug guidance from the FDA for its ketamine compound therapy.
Santa Barbara, California-based Bexson develops the patented BB106 formulation, a ketamine therapy delivered through a wearable, subcutaneous patch pump in development with Stevanato Group.
Get the full story at our sister site, Drug Delivery Business News.